A5055159334- Lung Cancer Treatments and Mutations
- PARP inhibition in cancer therapy
- Cancer Genomics and Diagnostics
- Cancer therapeutics and mechanisms
- Pancreatic and Hepatic Oncology Research
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Genetic factors in colorectal cancer
- Colorectal Cancer Treatments and Studies
- Neutropenia and Cancer Infections
- Cancer Treatment and Pharmacology
- Cancer Research and Treatments
- DNA Repair Mechanisms
- Gastric Cancer Management and Outcomes
- Colorectal and Anal Carcinomas
- Renal cell carcinoma treatment
- Prostate Cancer Treatment and Research
- Monoclonal and Polyclonal Antibodies Research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Radiomics and Machine Learning in Medical Imaging
- Neuroendocrine Tumor Research Advances
- Radiopharmaceutical Chemistry and Applications
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer, Stress, Anesthesia, and Immune Response
- Cancer-related gene regulation
Yale University
2016-2025
Yale Cancer Center
2016-2025
University of New Haven
2023-2025
Chinese Academy of Medical Sciences & Peking Union Medical College
2021
Fujian Medical University
2021
Sunnybrook Health Science Centre
2016-2021
Health Sciences Centre
2016-2021
University of Toronto
2016-2021
Smilow Cancer Hospital
2017-2020
Yale New Haven Hospital
2016
Abstract Introduction Personalized and tumor-informed circulating tumor DNA (ctDNA) testing is feasible allows for molecular residual disease (MRD) identification in patients with pancreatic ductal adenocarcinoma (PDAC). Methods In this retrospective analysis of commercial cases from multiple US institutions, personalized, tumor-informed, whole-exome sequenced, germline-controlled ctDNA levels were quantified analyzed PDAC. Plasma samples (n = 1329) 298 clinically validated collected at...
Abstract Background Neomorphic isocitrate dehydrogenase ( IDH ) mutations lead to the accumulation of 2‐hydroxyglutarate (2‐HG), an oncometabolite implicated in tumor progression via inhibitory effects on alpha‐ketoglutarate. Moreover, mutant –dependent 2‐HG results homologous recombination deficiency (HRD), which preclinically renders tumors sensitive poly(adenosine diphosphate ribose) polymerase inhibitors. Here, cholangiocarcinoma (CCA) arm National Cancer Institute (NCI) 10129 olaparib...
TAS-102 (trifluridine and tipiracil hydrochloride; a novel combination oral nucleoside anti-tumor agent) has recently received regulatory approval for patients with refractory metastatic colorectal cancer (mCRC). Internal review of data at single-institution showed trend towards better overall survival (OS) who experienced chemotherapy-induced neutropenia 1-month (CIN-1-month). To explore this finding further, cohort study was designed based on outcome from three centers in United States one...
Importance Improvements in cancer outcomes have led to a need better understand long-term oncologic and nononcologic quantify cancer-specific vs noncancer-specific mortality risks among survivors. Objective To assess absolute relative rates survivors of cancer, as well associated risk factors. Design, Setting, Participants This cohort study included 627 702 patients the Surveillance, Epidemiology, End Results registry with breast, prostate, or colorectal who received diagnosis between...
Checkpoint inhibitors represent an effective treatment approach for a variety of cancers through their inhibition immune regulatory pathways within the tumor microenvironment (TME). Unfortunately only minority patients with cancer achieve clinical benefit from immunotherapy, TME emerging as important predictor outcomes and sensitivity to therapy. The extent pattern T-cell infiltration can vary prominently within/across tumors represents biological continuum. Three profiles have been...
2502 Background: AhR activation is involved in tumor growth, immunomodulation, and resistance to immune checkpoint inhibitors. BAY2416964 a novel, potent, oral inhibitor (AhRi) that antagonizes ligand-induced immunosuppressive effects, resulting enhanced proinflammatory activity of antigen-presenting cells T reduced myeloid cells. Methods: A first-in-human, Phase I clinical trial AhRi (NCT04069026) evaluating its safety, pharmacokinetics, pharmacodynamics, recommended II dose, anti-tumor per...
Studies from several countries have documented gender disparities in the management of coronary artery disease. Whether such are seen Italy and, if so, whether they can be explained by factors as age and severity illness were investigated.77 974 Piedmontese patients, admitted between 1999 2002, with a primary diagnosis myocardial infarction (ICD 410), angina 413), chronic ischaemia 414) chest pain 786.5) studied. The number men women undergoing surgical treatment was extracted male-female...
This study sought to assess microsatellite and KRAS status, prevalence, impact on outcome in stage IV colorectal cancer (CRC).The 2010 2016 US National Cancer Database was queried for adult patients with CRC. Prevalence of status (microsatellite instability-high [MSI-H] or stable [MSS]) (KRAS mutation wild-type) the primary CRC assessed. Overall survival (OS) evaluated using multivariable Cox proportional hazards models complete data both information follow-up.Information available 10,844...
TPS3175 Background: The Wnt/β-catenin pathway is a frequently activated oncogenic and well-described driver of many cancers. FOG-001 designed to be first-in-class direct inhibitor β-catenin that blocks β-catenin’s interaction with the T-cell factor (TCF) family transcription factors. Preclinical studies have indicated can cause tumor growth inhibition regression by disrupting β-catenin-dependent signaling. unique from previously reported modulators as it directly inhibit TCF interaction,...
247 Background: MET signaling is implicated in the tumorigenesis of many solid tumors, including CRC. MET-targeted therapies are approved non-small cell lung cancer with novel agents clinical trials for tumors exon 14 splice site mutations, amplifications, and recently expression. There emerging therapeutic interest targeting Methods: Tumor samples from 50,500 cases clinically advanced CRC were analyzed by hybrid capture-based comprehensive genomic profiling (CGP) that evaluated all classes...
123 Background: BGB-B167 is potentially a first-in-class IgG-based bispecific antibody that targets CEA, tumor-associated antigen overexpressed in many cancers, and 4-1BB, key T-cell co-stimulatory receptor expressed on activated CD4+/CD8+ T lymphocytes. Preclinical data suggest binds to these target proteins with high specificity/affinity, inducing activation antitumor activity, potential for mitigating strong AEs, eg CRS hepatoxicity. We present results of first-in-human, phase 1a,...
238 Background: There have been significant advancements in novel therapies that target the DNA damage response pathway, and utilizing scar-based measures of homologous recombination deficiency (HRD) beyond genomic alterations (GA) BRCA1/2 may provide opportunities for additional biomarker-driven patients with advanced CRC. Methods: We identified 47,028 cases CRC comprehensive profiling (CGP) to examine all classes GA measure HRDsig+ status. HRDsig status was calculated using a broad set...
258 Background: Telisotuzumab adizutecan is an antibody-drug conjugate comprising the c-Met–targeting antibody telisotuzumab conjugated to a topoisomerase 1 inhibitor payload, adizutecan. A phase trial (NCT05029882) in advanced solid tumors reported higher response rates pts with CRC and high c-Met expression. We present analysis of responses based on genomic alterations ctDNA. Methods: Pts that refractory standard treatment were enrolled. was given IV Q3W. ctDNA isolated from baseline (BL)...
TPS322 Background: Wnt/B-catenin pathway activation, which is frequently present in most colorectal cancers and a variety of other solid tumors, associated with poor prognosis resistance to immunotherapy. FOG-001 Helicon peptide that competitively inhibits the interaction between β-catenin T-cell factor (TCF) family transcription factors. Experiments patient-derived-xenograft (PDX) models cancer (CRC) hepatocellular carcinoma (HCC) have demonstrated can inhibit tumor growth promote...
65 Background: Frailty, a pathologic form of aging, is associated with reduced quality life and increased risk death. Its incidence increases age. Frailty concern for cancer survivors, especially since this population surviving longer increasing in size. There need to predict which patients are at frailty tailor preventative measures, particularly early-stage colon rectal the largest group gastrointestinal survivors. Methods: This was retrospective cohort study individuals aged 66 older...
45 Background: dMMR tumors are characterized by rapid primary tumor growth with reduced likelihood for nodal and distant metastases compared to MMR proficient (pMMR) tumors. Neoadjuvant immune checkpoint inhibitors (ICIs) have demonstrated promising efficacy localized colon cancer high pathologic complete response rates low relapse rates. This raises the question if surgical treatment could be avoided accurate radiographic staging while avoiding overtreatment of early stage study assesses...
66 Background: There are established features that predict early recurrence of CRC in the first 5 years from diagnosis, but predictors late 5-10 after diagnosis less well understood. Long-term survivors require multidisciplinary follow-up accounting for both cancer and non-cancer related conditions. Identifying disease-free survival may help inform survivorship care. Methods: This was a retrospective cohort study patients aged ≥66 SEER-Medicare database with non-metastatic diagnosed between...
PURPOSE The Cancer Genome Atlas (TCGA) classifies gastric cancer (GC) into four molecular subtypes: Epstein-Barr virus–positive, microsatellite instability–high (MSI-H), genomically stable (GS), and chromosomal instability (CIN). This exploratory analysis compared the genomic landscape of late-stage GC from KEYNOTE-059, KEYNOTE-061, KEYNOTE-062 studies with early-stage TCGA evaluated characteristics in patients Western Asian origin. MATERIALS AND METHODS Using pretreatment tumor samples,...
Abstract Background: The effects of neoadjuvant chemotherapy (NAC) and the survival impact tumor infiltrating lymphocytes (TILs) in colorectal cancer liver metastases (CRCLM) microenvironment (TME) remain poorly understood. Methods: We studied clinicopathologic characteristics levels different TIL subpopulations using multiplexed quantitative immunofluorescence (mQIF) paired primary/liver metastasis two independent CRCLM cohorts from Yale-New Haven Hospital between 2000-2024 tissue...
Abstract Background: CM24 (mAb) blocks CEACAM1 interactions between cancer cells, immune cells and neutrophil extracellular traps (NET), involved in tumor evasion, metastasis cancer-associated thrombosis, affecting patient (pts) survival. We present the final data for randomized Phase 2 study (NCT04731467) significant efficacy a biomarker-enriched subgroup. Methods: Advanced/metastatic PDAC pts (n=31) progressing after first line treatment, were to receive (20mg/kg q2wk), nivolumab (240mg/kg...